Contrarians POV

The conversations of online communities

action on rxIf pharma companies do not join the digital dialogue and influence the conversation, they will lose an opportunity to shape it, and they may be put on the defensive trying to refute the statements made by those that do take part. Continue reading »

Pfizer misses the mark with humor

offthemarkPfizer is adding humor to the battle over the post-menopause prescription market. Launched last week the “Let’s talk about change” campaign is a departure from the company’s recent “Tune into Menopause” campaign that featured Kim Cattrall.  As someone who has sat in a LOT of research with women this YouTube video really misses the mark. Continue reading »

Time to ditch ROI discussions for DTC Marketing

ditchroiPOST SUMMARY: It’s hard to have a meeting to discuss new DTC marketing initiatives without the dreaded ROI discussion. I understand that the current business environment in biopharma is about creating customers, but the problem is that consumers today don’t want to be sold.  If you really want to closer to your customers, find ways to help them make better healthcare decisions and get good credible health information. Continue reading »

The demise of biotech

AccCIO-Yikes-300x203POST SUMMARY:  Over the holiday week I had the chance to catch up with some business colleagues over a beer and great Boston seafood appetizers.  If you want an example how big pharma mentality can kill innovative biotech companies, look no further than the examples of Biogen and Amgen. Continue reading »

Pharma lagging in digital…

imagesPOST SUMMARY:  According to McKinsey&Company “unlike successful B2C companies in other industries— which offer mobile solutions, provide personalized product recommendations, and empower customer-service agents with a 360-degree view of the customer—most healthcare providers and payors are lagging, as are pharmaceutical companies and medical-device manufacturers.”  How much monger does pharma need to get the wake-up call? Continue reading »

Pradaxa: What’s a patient to do?

UnknownPOST SUMMARY: As we learn to think like patients one has to wonder just what the hell a patient on the blood thinner Pradaxa wants to do given the new research that indicates the product may not be as safe as they believed. Continue reading »

Is pharma its own worst enemy?

Make sure your worst enemy is not living between your own two earsOne of the questions I get asked and asked again is “why haven’t most pharma companies changes in their approach to DTC and digital marketing?”.  The answer to this is complex, but at its heart most major consulting research has indicated that time and time again pharma is a laggard when it comes to change and hiring people who can really question current thinking when it comes to meeting the needs of consumers of healthcare. Continue reading »

Share with your friends










Submit